A concise course of the history of NSAIDs

Каратеев, А. Е.; Uspensky, Yu. P.; Pakhomova, I G; Насонов, Евгений Львович

doi:10.14412/1995-4484-2012-718

Cited by 6 publications

(7 citation statements)

References 83 publications

(107 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Именно при приёме НПВС риск ятрогенной ко-морбидности и лекарственного взаимодействия становится особенно высоким и, соответственно, требует от практического врача своевременного проведения необходимых профилактических ме-роприятий [15,18,28,34,35].…”

Section: казанский медицинский журнал 2017 г том 98 №6unclassified

“…НПВСгастропатия -выявляемое при эн-доскопическом исследовании повреждение сли-зистой оболочки верхних отделов ЖКТ с фор-мированием эрозий и язв желудка и/или ДПК и развитием опасных, угрожающих жизни пациен-та осложнений -желудочно-кишечного крово-течения, перфорации язв, нарушения проходимо-сти ЖКТ [34,35].…”

Section: казанский медицинский журнал 2017 г том 98 №6unclassified

“…НПВС-ассоциированные язвы чаще еди-ничные, относительно небольшого размера и неглубокие. Множественные язвы вопреки суще-ствующему мнению развиваются относительно редко [15,34,35].…”

Section: казанский медицинский журнал 2017 г том 98 №6unclassified

“…НПВС-ассоциированные гастропатии воз-никают на ранних сроках от начала их приёма (в первые 3 мес), с наибольшей вероятностью разви-тия в 1-й месяц применения НПВС [34,35].…”

Section: казанский медицинский журнал 2017 г том 98 №6unclassified

“…При НПВС-ассоциированных язвах субъ-ективная симптоматика зачастую отсутствует, формируются так называемые «немые» язвы, в связи с чем эзофагогастродуоденоскопия служит единственным достоверным методом диагности-ки НПВС-гастропатии и контроля противоязвен-ной терапии при данной патологии [15,34,35].…”

Section: казанский медицинский журнал 2017 г том 98 №6unclassified

See 4 more Smart Citations

Comorbidity in the clinical presentation of internal diseases: focus on symptomatic gastroduodenal ulcers

et al. 2017

View full text Add to dashboard Cite

At present, comorbidity is one of the current interdisciplinary problems of clinical medicine. At the same time, in the modern literature the number of teaching and study guides, monographs and other scientific publications reflecting the essence of comorbidity and its prognostic significance for the patient, is clearly inadequate. Also, no national clinical guidelines exist for managing patients with comorbid diseases. The aim of the review is to draw practical physicians’ attention to the importance of timely detection of comorbid nature of the internal disease necessary for the correct choice of therapeutic measures for patients suffering from multiple diseases, early prevention of possible complications and the formation of a favorable prognosis. Symptomatic gastroduodenal ulcer lesions were chosen as one of the examples of comorbid pathology, late diagnosis and absence of early prevention of which can become the causes of gastrointestinal bleeding and related deaths in patients. The article reflects the definition of comorbidity, existing synonyms, its main types, and methods of evaluation. The causes and factors of the development of comorbid diseases, their prevalence in the population are analyzed. Attention is focused on the rules for formulation of clinical diagnosis for a comorbid patient, the need to take into account comorbidity when choosing an algorithm for integrated diagnosis and rational treatment of the disease. The importance of assessing the risk of drug interactions in the pharmacotherapy of comorbid diseases and possible complications are emphasized. The epidemiology of symptomatic gastroduodenal ulcers, their pathogenesis, common clinical presentation and its features depending on a specific type, complexity of diagnosis are analyzed in detail.

show abstract

Section: казанский медицинский журнал 2017 г том 98 №6unclassified

See 3 more Smart Citations

Comorbidity in the clinical presentation of internal diseases: focus on symptomatic gastroduodenal ulcers

et al. 2017

View full text Add to dashboard Cite

show abstract

Modern view on the effectiveness and safety of non-steroidal anti-inflammatory drugs

Shamal,

Shelemekh,

Murashko

et al. 2024

Rev Clin Pharm Drug Ther

View full text Add to dashboard Cite

Issues of the effectiveness and safety of drugs continue to be relevant and controversial. The benefits and risks of drug therapy are two facets of one whole, called pharmacotherapy, and can turn out to be an undesirable side and even outweigh the benefits with a large negative value. The effectiveness and safety of drugs requires serious study also because it becomes possible to discover new effects of drugs and reveal new mechanisms for unregistered indications and, at the same time, a deep understanding of adverse drug reactions will allow more correct prescribing of drugs and proper medical supervision of therapy. Nonsteroidal anti-inflammatory drugs (NSAIDs) are over-the-counter drugs and are perceived by a wide range of patients as safe drugs that do not require a doctor’s prescription, which can cause dangerous drug reactions, especially when used uncontrollably. The review presents literature data from studies of the effectiveness of NSAIDs and current data on new therapeutic effects of individual drugs, as well as the risks of adverse reactions, their mechanisms and methods of correction.

show abstract

New therapeutic options for musculoskeletal pain

Данилов

Коржавина

2019

Med. sov.

View full text Add to dashboard Cite

Musculoskeletal pain (MSP) is one of the major interdisciplinary problems of modern medicine and society. Inflammation is a universal mechanism that plays a crucial role in the development of acute and chronic MSP. Therefore, non-steroidal antiinflammatory drugs (NSAIDs) are the first-line treatment for MSP. The effectiveness of all NSAIDs in reducing pain and inflammation is approximately the same, and the degree of safety is determined by their relationship to COX-1 and COX-2 enzymes. Thanks to pharmacological properties and a balanced profile of efficiency and safety, the successful position of the «golden mean» between cokebins and non-selective NSAIDs is a moderately selective aceklofenac, which makes it appropriate for the vast majority of patients with MSP. Introduction into clinical practice of the drug Aceklagin containing 200 mg of aceсlofenaс in a new drug form with modified two-phase release, opens up new possibilities of MSP therapy. Due to the stable concentration of aceclofenac in the body during the day, Aceklagin improves the efficiency of pain and inflammation treatment in patients with MSP, while maintaining a high level of safety inherent in this molecule.

show abstract

A concise course of the history of NSAIDs

Cited by 6 publications

References 83 publications

Comorbidity in the clinical presentation of internal diseases: focus on symptomatic gastroduodenal ulcers

Comorbidity in the clinical presentation of internal diseases: focus on symptomatic gastroduodenal ulcers

Modern view on the effectiveness and safety of non-steroidal anti-inflammatory drugs

New therapeutic options for musculoskeletal pain

Contact Info

Product

Resources

About